A pilot clinical study to evaluate feasibility of using single patient classifier as a prognostic test in stage Ⅱ-Ⅲ gastric cancer patients
作者机构：Department of Surgery Samsung Medical Center Sungkyunkwan University School of Medicine Department of Pathology and Translational Genomics Samsung Medical Center Sungkyunkwan University School of Medicine Department of Surgery Yonsei University College of Medicine Gastric Cancer Center Yonsei Cancer CenterYonsei University Health System Center for Gastric Cancer National Cancer Center Department of Surgery Chonnam National University Hwasun Hospital Chonnam National University College of Medicine Department of Surgery Gangnam Severance Hospital Yonsei University College of Medicine Department of Hematology-Oncology Yeungnam University Medical Center Department of SurgerySoonchunhyang University College of Medicine Department of Surgery Soonchunhyang University Cheonan Hospital Soonchunhyang University College of Medicine Department of Surgery Chung-Ang University Hospital Chung-Ang University College of Medicine
出 版 物：《Chinese Journal of Cancer Research》 (中国癌症研究(英文版))
年 卷 期：2024年第36卷第4期
页 面：368-378页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：partial financial support provided by Novomics (Seoul Korea)
主 题：Prognostic test adjuvant chemotherapy advanced gastric cancer feasibility gastrectomy
摘 要：Objective: Precision medicine approaches emphasize the importance of reliable prognostic tools for guiding individualized therapy decisions. In this study, we evaluated the clinical feasibility of the single patient classifier(SPC) test, a new clinical-grade prognostic assay, in stage Ⅱ-Ⅲ gastric cancer ***: A prospective multicenter study was conducted, involving 237 patients who underwent gastrectomy between September 2019 and August 2020 across nine hospitals. The SPC test was employed to stratify patients into risk groups, and its feasibility and performance were evaluated. The primary endpoint was the proportion of the cases in which the test results were timely delivered before selecting postoperative treatment. Furthermore, 3-year disease-free survivals of risk groups were ***: The SPC test met the primary endpoint criteria. The 99.5% of SPC tests were timely delivered to hospitals before the postoperative treatment started. In a clinical setting, the median time from the specimen transfer to laboratory to the result delivery to hospital was 4 d. Furthermore, 3-year disease-free survivals were significantly different between risk groups classified with SPC ***: This study highlights the SPC test s feasibility in offering crucial information timely delivered for making informed decisions regarding postoperative treatment strategies. It also provides evidence to support the implementation of a future prospective clinical trial aimed at evaluating the clinical utility of the SPC test in guiding personalized treatment decisions for gastric cancer patients.
同方期刊数据库